Bayer Aktiengesellschaft (ETR:BAYN) Trading 0% Higher - Still a Buy?

Key Points

• Bayer Aktiengesellschaft's stock price remains stable, trading at around €27.51 ($32.36) with a market capitalization of $27.87 billion.
• The company has a negative PE ratio of -31.68 and a price-to-earnings-growth ratio of 36.39, indicating challenges in profitability.
• Bayer operates in three segments: Pharmaceuticals, Consumer Health, and Crop Science, focusing on areas like oncology and women's health care.

Bayer Aktiengesellschaft (ETR:BAYN - )'s stock price traded up 0% on Wednesday . The company traded as high as €27.57 ($32.43) and last traded at €27.51 ($32.36). 1,720,747 shares were traded during mid-day trading, The stock had previously closed at €27.50 ($32.35).

Bayer Aktiengesellschaft Stock Performance

The stock has a market capitalization of $27.87 billion, a PE ratio of -31.68, a price-to-earnings-growth ratio of 36.39 and a beta of 0.97. The business's 50-day moving average is €27.70 and its two-hundred day moving average is €25.31.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.